COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ARGENTINA

被引：0
|
作者：
Rodriguez, L. [1 ]
Lew, D. [2 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Buenos Aires, DF, Argentina
[2] Austral Hosp, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB39
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
  • [2] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Apostolos Tsapas
    Georgia Kourlaba
    Giannis Papageorgiou
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2018, 38 : 417 - 426
  • [3] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsapas, Apostolos
    Kourlaba, Georgia
    Papageorgiou, Giannis
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 417 - 426
  • [4] COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
    Gourzoulidis, G.
    Tzanetakos, C.
    Ioannidis, I.
    Tsapas, A.
    Kourlaba, G.
    Papageorgiou, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [5] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
    Mannucci, Edoardo
    Ghetti, Gianni
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 85 - 95
  • [6] Cost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patients
    Maciel, Olga
    Vera, Zully
    Marin, Gustavo H.
    Morinigo, Macarena
    Maidana, Mabel
    Mastroianni, Patricia
    [J]. RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2018, 9 (05): : 1824 - 1829
  • [7] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [8] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    [J]. Cost Effectiveness and Resource Allocation, 19
  • [9] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [10] Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China
    Salem, Ahmed
    Men, Peng
    Ramos, Mafalda
    Zhang, Yan-Jun
    Ustyugova, Anastasia
    Lamotte, Mark
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 469 - 480
12345